Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced positive clinical data from its Phase 1b trial of azenosertib in advanced platinum-resistant ovarian cancer at the ASCO Meeting scheduled for June 2-6, 2023. The trial focuses on the correlation between Cyclin E1 expression and clinical outcomes, suggesting that azenosertib may restore chemotherapy sensitivity in resistant cancers. Zentalis also formed collaborations with Foundation Medicine and Roche Diagnostics to enhance genomic profiling and develop diagnostic assays for patient identification in ongoing clinical trials. These partnerships aim to identify patients who can benefit significantly from azenosertib, underscoring its potential as a first-in-class therapy. The company is evaluating azenosertib in various settings, including as a monotherapy and in combination therapies.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has presented preclinical data at the AACR Annual Meeting, underscoring the role of Cyclin E1 as a predictive marker for the treatment of platinum-resistant ovarian cancer with azenosertib, its Wee1 inhibitor candidate. Findings indicate that tumors with high Cyclin E1 expression are more responsive to azenosertib, showing significant cancer cell death in laboratory settings. The company anticipates revealing further clinical data from its ongoing studies in the first half of 2023, ahead of earlier timelines. This research may pave the way for developing companion diagnostics and improving patient outcomes. Zentalis is evaluating azenosertib across various clinical trials for solid tumors and hematological malignancies, aiming to establish its potential as a first-in-class therapy.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported its financial results for 2022, highlighting progress on its lead candidate azenosertib, a Wee1 inhibitor. The company is on track to declare the monotherapy recommended Phase 2 dose in 1H 2023 and is pursuing a Cyclin E1 patient enrichment strategy for ovarian cancer treatment. Zentalis has also initiated enrollment in a Phase 1/2 study of azenosertib with Pfizer for metastatic colorectal cancer. The company ended 2022 with a robust cash balance of $437 million, sufficient to fund operations into Q2 2025. R&D expenses decreased slightly, while G&A expenses grew due to increased workforce costs.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has appointed Iris Roth, PhD, as Chief Operating Officer, enhancing its leadership team with her extensive oncology experience. Dr. Roth, formerly at GlaxoSmithKline, has successfully developed various cancer therapies and will aid Zentalis in advancing its clinical strategy. CEO Dr. Kimberly Blackwell expressed confidence in Dr. Roth's capabilities to foster effective drug development. Zentalis aims to release updated program timelines and potential registration paths soon, focusing on its promising pipeline that includes azenosertib and ZN-d5.